109
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells

ORCID Icon, , , , , , , , & show all
Pages 3451-3459 | Received 10 Feb 2020, Accepted 07 Aug 2020, Published online: 28 Aug 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yuhua Li, Zhengzheng Liao, Xiaohua Wei, Xiong Xiao & Jinfang Hu. (2022) Epifriedelanol enhances adriamycin-induced cytotoxicity towards K562/ADM cells by down regulating of P-gp and MRP2. Xenobiotica 52:4, pages 389-396.
Read now

Articles from other publishers (3)

Ilknur SUER & Murat KAYA. (2023) Is the AURKB Gene Involved in Aml Cell Proliferation Since It is Targeted by miR-34a-5p and let-7b-5p?AURKB Geni miR-34a-5p ve let-7b-5p Tarafından Hedeflendiğinden AML Hücre Proliferasyonunda Rol Oynar mı?. Konuralp Tıp Dergisi 15:1, pages 16-23.
Crossref
Shuangqin Peng, Yanjun Luo, Lijuan Chen, Kang Dai & Qin Wang. (2022) lncRNA ELFN1-AS1 enhances the progression of colon cancer by targeting miR-4270 to upregulate AURKB. Open Medicine 17:1, pages 1999-2012.
Crossref
HAN ZHAO, JING GUO, QINGJIA CHI & MENG FANG. (2022) Molecular mechanisms of Tanshinone IIA in Hepatocellular carcinoma therapy via WGCNA-based network pharmacology analysis. BIOCELL 46:5, pages 1245-1259.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.